Medication contraindications and safety precautions for canafenib/encofenib (bitavir)

Encorafenib (Encorafenib) is a BRAF kinase inhibitor, mainly suitable for patients with BRAF V600E or V600K Mutated unresectable or metastatic melanoma has also been explored in some studies as a treatment for colorectal cancer and other BRAFmutated tumors. It is often used in combination with the MEK inhibitor trametinib (Trametinib) or bimetinib (Binimetinib) to improve efficacy and reduce the risk of drug resistance. Although the drug shows good therapeutic prospects in clinical application, contraindications and multi-faceted safety management must be paid attention to during use to maximize efficacy and reduce risks.

1. Medication contraindications

1.BRAFContraindicated in patients with wild-type tumors

Encofenib is only effective in patients with tumors carrying BRAF V600 mutations. If used in patients with BRAF wild-type tumors, it may lead to accelerated tumor progression. Therefore, molecular testing must be used to confirm the presence of the relevant mutation in the patient before starting treatment.

2.Contraindicated for those who are allergic to drug ingredients

Patients with a history of severe allergic reaction to encofenib or any excipients in the preparation should not use it to avoid the occurrence of severe allergy or anaphylactic shock.

3. Use with caution or prohibition in patients with severe liver damage

Encofenib is metabolized in the liver, and the plasma concentration may increase in patients with severe hepatic insufficiency, increasing the risk of toxicity. Therefore, its use should be avoided in Child-Pugh C patients.

4. Contraindicated during pregnancy and lactation

Existing research shows that encofenib may cause harm to the fetus. Pregnant women are prohibited from using it, and reliable contraceptive measures should be taken during treatment and for at least a few months after the end of treatment. Breast-feeding women should also avoid use, because the drug may be secreted through breast milk and have adverse effects on the baby.

2. Main safety precautions

1.Risk of cardiotoxicity

Encofenib may cause QT interval prolongation and increase the risk of arrhythmia. Before taking medication, patients should undergo electrocardiogram examination and electrolyte assessment, and electrocardiogram and serum electrolytes need to be monitored regularly during medication. Caution is required when concomitant use of other drugs that prolong the QT interval, such as antiarrhythmic drugs (amiodarone, sotalol, etc.) or some antipsychotics.

2.Liver function monitoring

Since this drug is mainly metabolized by the liver, liver function (ALT, AST, bilirubin, etc.) needs to be checked regularly during medication. If obvious liver function abnormalities occur, dose reduction, temporary drug withdrawal, or discontinuation should be considered.

3.Adverse skin reactions

Encofenib may cause rash, photosensitivity reactions, and secondary skin tumors (such as squamous cell carcinoma, basal cell carcinoma). Therefore, dermatological examinations should be performed regularly during treatment, and patients should pay attention to sun protection and avoid prolonged exposure to strong light or ultraviolet rays.

4.Ocular toxicity

Retinal vein occlusion or retinal pigment epithelial detachment may occur when used in combination with MEK inhibitors. If blurred vision, floaters, or visual field defects occur, the drug should be discontinued immediately and an eye examination should be performed.

5.Risk of bleeding

Bleeding events have occurred in some patients in clinical studies, especially when the drug was combined. For patients with bleeding tendencies or who are taking anticoagulants or antiplatelet drugs, the risk should be carefully assessed.

6.Gastrointestinal adverse reactions

Common side effects of encofenib include nausea, vomiting, diarrhea, and loss of appetite. Patients should take the medication with meals to reduce discomfort, and may use antiemetics or antidiarrheals if necessary.

3. Drug interaction management

Encofenib is mainly metabolized by the CYP3A4 enzyme system. Therefore, the combined use of strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampicin, carbamazepine, St. John's wort) will significantly change the drug's blood concentration, affect the efficacy or increase toxicity. Clinically, such combination should be avoided as much as possible. If coadministration is necessary, adverse reactions should be closely monitored and dosages adjusted appropriately.

4. Precautions for special groups of people

1.Elderly patients

Although encofenib can be used in the elderly, their heart, liver and kidney functions decline and require closer monitoring.

2.People with renal insufficiency

No dose adjustment is required in patients with mild to moderate renal impairment, but clinical data in people with severe renal impairment are limited and caution should be used.

3.Women and men of childbearing age

Women must use strict contraception while taking the drug; men are also advised to take effective contraceptive measures to avoid potential risks to sperm or offspring.

Encorafenib (Encorafenib) is an oral drug targeting BRAF V600 mutation. It has significant anti-tumor activity, but safety management must be strictly followed during medication. Its main contraindications include non-BRAF mutated tumors, severe liver damage, pregnancy and lactation, and drug allergies. During medication, it is necessary to focus on monitoring cardiotoxicity, liver function, skin reactions, eye health and potential bleeding risks. In addition, care should be taken to avoid concomitant use with strong inhibitors or inducers of CYP3A4. Through individualized monitoring and risk management, drug-related adverse reactions can be reduced while maximizing efficacy, providing patients with safer and more effective treatment options.

Reference materials:https://www.drugs.com/